Technology

Fulcrum Therapeutics

$13.95
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.22 (+18.93%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell FULC and other stocks, options, and ETFs commission-free!

About FULC

Fulcrum Therapeutics, Inc. Common Stock, also called Fulcrum Therapeutics, is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA. The listed name for FULC is Fulcrum Therapeutics, Inc. Common Stock.

CEO
Robert J. Gould
Employees
73
Headquarters
Cambridge, Massachusetts
Founded
2015
Market Cap
383.10M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
97.36K
High Today
$13.98
Low Today
$11.67
Open Price
$12.00
Volume
1.48M
52 Week High
$22.39
52 Week Low
$7.01

Collections

FULC Earnings

-$9.21
-$6.14
-$3.07
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 4, Pre-Market

You May Also Like

CHNG
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure